Clinical Trial Update: A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ridaforolimus in combination with dalotuzumab versus standard of care in estrogen receptor-positive breast cancer has completed. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Dalotuzumab (dalotuzumab)
• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED